Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Apr 26, 2022 8:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update

Mar 08, 2022 8:05am EST

Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology

Mar 01, 2022 4:01pm EST

Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Feb 22, 2022 8:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

Jan 10, 2022 4:15pm EST

Rigel to Present at the J.P. Morgan Healthcare Conference

Jan 10, 2022 8:40am EST

Rigel Pharmaceuticals Provides Business Update

Dec 21, 2021 8:30am EST

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

Dec 16, 2021 9:00am EST

Rigel Appoints Kamil Ali-Jackson to Board of Directors

Nov 15, 2021 8:30am EST

Rigel Sharpens Focus on Its Advanced Portfolio Opportunities

Nov 09, 2021 7:30am EST

Rigel to Participate in Two Upcoming Investor Conferences

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin